ICBII Update on the Road to the Cure - July 2023

A Real-Time Science Report

This is a reprint of a previous report. Dr. Bhatt will be back next month with a fresh update. 

This article focuses on a potential common link related to the dysfunctional synaptic plasticity that science associates with neurodegenerative disorders such as Parkinson’s, Alzheimer’s, and schizophrenia. A specific protein implicated in the cognitive decline of Alzheimer’s also appears to play a role in the genetic predisposition to Parkinson’s and schizophrenia, meaning that a drug that targets that protein could potentially treat a variety of neuropsychiatric disorders, according to a study published in the Journal of Molecular Psychiatry.

This protein is known as Striatal-Enriched Protein Tyrosine Phosphatase (STEP) and plays an important role in the healthy functioning of synapses, the connections between brain cells. Excessive amounts of STEP protein are found in the brains of humans and animal models of Alzheimer’s disease, Parkinson’s, Fragile X Syndrome, and schizophrenia. The increase in STEP leads to a disruption of synaptic function and contributes to the cognitive deficits present in these disorders.

An experimental drug designed to inhibit the STEP protein restores cognitive deficits in a mouse model of Alzheimer’s disease. The researchers have shown that genetically eliminating STEP or using the drug to inhibit STEP activity improves cognitive deficits in a mouse model that has behavioral features related to symptoms of schizophrenia. Unfortunately, these small molecule drugs stop working after a while as is the case with L-Dopa.

These findings suggest that a STEP inhibitor if developed, may be the basis of a new drug that can treat any number of neurodegenerative diseases, including Parkinson’s.

Good News
ICB International, Inc. has the technology to develop inhibitors of STEP protein. The Company plans to start a research program to develop STEP-SMART Molecules to restore cognition of Alzheimer’s, Parkinson’s, and schizophrenia patients and provide these patients a chance to live a normal life. 

ADDITIONALLY, WOULD YOU LIKE TO HELP get ICBII’s drugs to market faster? The joy of being a part of these historical events can be had by helping ICBII find the funds to bring these trials to fruition through your investing, and by finding others with the financial ability and humanitarian mindset to accomplish the, until now, impossible. Please contact ICBII directly through their website ICBII.com or by phone 858-455-9880, or contact Jo Rosen at PRO for a personal introduction to the scientists.

IMAGINE the world without Parkinson’s, MSA, or Alzheimer’s disease.

JUST IMAGINE.